Costs of hospitalization in preterm infants: impact of antenatal steroid therapy

Detalhes bibliográficos
Autor(a) principal: Ogata,Joice Fabiola Meneguel
Data de Publicação: 2016
Outros Autores: Fonseca,Marcelo Cunio Machado, Miyoshi,Milton Harumi, Almeida,Maria Fernanda Branco de, Guinsburg,Ruth
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal de Pediatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572016000100024
Resumo: ABSTRACT OBJECTIVE: To estimate the costs of hospitalization in premature infants exposed or not to antenatal corticosteroids (ACS). METHOD: Retrospective cohort analysis of premature infants with gestational age of 26-32 weeks without congenital malformations, born between January of 2006 and December of 2009 in a tertiary, public university hospital. Maternal and neonatal demographic data, neonatal morbidities, and hospital inpatient services during the hospitalization were collected. The costs were analyzed using the microcosting technique. RESULTS: Of 220 patients that met the inclusion criteria, 211 (96%) charts were reviewed: 170 newborns received at least one dose of antenatal corticosteroid and 41 did not receive the antenatal medication. There was a 14-37% reduction of the different cost components in infants exposed to ACS when the entire population was analyzed, without statistical significance. Regarding premature infants who were discharged alive, there was a 24-47% reduction of the components of the hospital services costs for the ACS group, with a significant decrease in the length of stay in the neonatal intensive care unit (NICU). In very-low birth weight infants, considering only the survivors, ACS promoted a 30-50% reduction of all elements of the costs, with a 36% decrease in the total cost (p = 0.008). The survivors with gestational age <30 weeks showed a decrease in the total cost of 38% (p = 0.008) and a 49% reduction of NICU length of stay (p = 0.011). CONCLUSION: ACS reduces the costs of hospitalization of premature infants who are discharged alive, especially those with very low birth weight and <30 weeks of gestational age.
id SBPE-1_d1fe810c087736d715b2cc40a4bf4d08
oai_identifier_str oai:scielo:S0021-75572016000100024
network_acronym_str SBPE-1
network_name_str Jornal de Pediatria (Online)
repository_id_str
spelling Costs of hospitalization in preterm infants: impact of antenatal steroid therapyPreterm infantCosts and cost analysisHospitalizationGlucocorticoidsABSTRACT OBJECTIVE: To estimate the costs of hospitalization in premature infants exposed or not to antenatal corticosteroids (ACS). METHOD: Retrospective cohort analysis of premature infants with gestational age of 26-32 weeks without congenital malformations, born between January of 2006 and December of 2009 in a tertiary, public university hospital. Maternal and neonatal demographic data, neonatal morbidities, and hospital inpatient services during the hospitalization were collected. The costs were analyzed using the microcosting technique. RESULTS: Of 220 patients that met the inclusion criteria, 211 (96%) charts were reviewed: 170 newborns received at least one dose of antenatal corticosteroid and 41 did not receive the antenatal medication. There was a 14-37% reduction of the different cost components in infants exposed to ACS when the entire population was analyzed, without statistical significance. Regarding premature infants who were discharged alive, there was a 24-47% reduction of the components of the hospital services costs for the ACS group, with a significant decrease in the length of stay in the neonatal intensive care unit (NICU). In very-low birth weight infants, considering only the survivors, ACS promoted a 30-50% reduction of all elements of the costs, with a 36% decrease in the total cost (p = 0.008). The survivors with gestational age <30 weeks showed a decrease in the total cost of 38% (p = 0.008) and a 49% reduction of NICU length of stay (p = 0.011). CONCLUSION: ACS reduces the costs of hospitalization of premature infants who are discharged alive, especially those with very low birth weight and <30 weeks of gestational age.Sociedade Brasileira de Pediatria2016-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572016000100024Jornal de Pediatria v.92 n.1 2016reponame:Jornal de Pediatria (Online)instname:Sociedade Brasileira de Pediatria (SBP)instacron:SBPE10.1016/j.jped.2015.03.004info:eu-repo/semantics/openAccessOgata,Joice Fabiola MeneguelFonseca,Marcelo Cunio MachadoMiyoshi,Milton HarumiAlmeida,Maria Fernanda Branco deGuinsburg,Rutheng2018-04-24T00:00:00Zoai:scielo:S0021-75572016000100024Revistahttp://www.jped.com.br/https://old.scielo.br/oai/scielo-oai.php||jped@jped.com.br1678-47820021-7557opendoar:2018-04-24T00:00Jornal de Pediatria (Online) - Sociedade Brasileira de Pediatria (SBP)false
dc.title.none.fl_str_mv Costs of hospitalization in preterm infants: impact of antenatal steroid therapy
title Costs of hospitalization in preterm infants: impact of antenatal steroid therapy
spellingShingle Costs of hospitalization in preterm infants: impact of antenatal steroid therapy
Ogata,Joice Fabiola Meneguel
Preterm infant
Costs and cost analysis
Hospitalization
Glucocorticoids
title_short Costs of hospitalization in preterm infants: impact of antenatal steroid therapy
title_full Costs of hospitalization in preterm infants: impact of antenatal steroid therapy
title_fullStr Costs of hospitalization in preterm infants: impact of antenatal steroid therapy
title_full_unstemmed Costs of hospitalization in preterm infants: impact of antenatal steroid therapy
title_sort Costs of hospitalization in preterm infants: impact of antenatal steroid therapy
author Ogata,Joice Fabiola Meneguel
author_facet Ogata,Joice Fabiola Meneguel
Fonseca,Marcelo Cunio Machado
Miyoshi,Milton Harumi
Almeida,Maria Fernanda Branco de
Guinsburg,Ruth
author_role author
author2 Fonseca,Marcelo Cunio Machado
Miyoshi,Milton Harumi
Almeida,Maria Fernanda Branco de
Guinsburg,Ruth
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Ogata,Joice Fabiola Meneguel
Fonseca,Marcelo Cunio Machado
Miyoshi,Milton Harumi
Almeida,Maria Fernanda Branco de
Guinsburg,Ruth
dc.subject.por.fl_str_mv Preterm infant
Costs and cost analysis
Hospitalization
Glucocorticoids
topic Preterm infant
Costs and cost analysis
Hospitalization
Glucocorticoids
description ABSTRACT OBJECTIVE: To estimate the costs of hospitalization in premature infants exposed or not to antenatal corticosteroids (ACS). METHOD: Retrospective cohort analysis of premature infants with gestational age of 26-32 weeks without congenital malformations, born between January of 2006 and December of 2009 in a tertiary, public university hospital. Maternal and neonatal demographic data, neonatal morbidities, and hospital inpatient services during the hospitalization were collected. The costs were analyzed using the microcosting technique. RESULTS: Of 220 patients that met the inclusion criteria, 211 (96%) charts were reviewed: 170 newborns received at least one dose of antenatal corticosteroid and 41 did not receive the antenatal medication. There was a 14-37% reduction of the different cost components in infants exposed to ACS when the entire population was analyzed, without statistical significance. Regarding premature infants who were discharged alive, there was a 24-47% reduction of the components of the hospital services costs for the ACS group, with a significant decrease in the length of stay in the neonatal intensive care unit (NICU). In very-low birth weight infants, considering only the survivors, ACS promoted a 30-50% reduction of all elements of the costs, with a 36% decrease in the total cost (p = 0.008). The survivors with gestational age <30 weeks showed a decrease in the total cost of 38% (p = 0.008) and a 49% reduction of NICU length of stay (p = 0.011). CONCLUSION: ACS reduces the costs of hospitalization of premature infants who are discharged alive, especially those with very low birth weight and <30 weeks of gestational age.
publishDate 2016
dc.date.none.fl_str_mv 2016-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572016000100024
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572016000100024
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.jped.2015.03.004
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Pediatria
publisher.none.fl_str_mv Sociedade Brasileira de Pediatria
dc.source.none.fl_str_mv Jornal de Pediatria v.92 n.1 2016
reponame:Jornal de Pediatria (Online)
instname:Sociedade Brasileira de Pediatria (SBP)
instacron:SBPE
instname_str Sociedade Brasileira de Pediatria (SBP)
instacron_str SBPE
institution SBPE
reponame_str Jornal de Pediatria (Online)
collection Jornal de Pediatria (Online)
repository.name.fl_str_mv Jornal de Pediatria (Online) - Sociedade Brasileira de Pediatria (SBP)
repository.mail.fl_str_mv ||jped@jped.com.br
_version_ 1752122320469622784